Primary Objective: To assess oncologists’ knowledge of Vectibix indication following the changes of
label about the appropriate use of Vectibix in mCRC patients regarding tumor KRAS status in selected
European countries, including the following specific aspects:
• Vectibix is indicated for the treatment of patients with wild-type KRAS metastatic colorectal
cancer (mCRC) in first line in combination with FOLFOX and in second line in combination with
FOLFIRI in patients who have received first–line fluoropyrimidine-based chemotherapy (excluding
irinotecan) and as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecancontaining
chemotherapy regimens
• Testing for KRAS should be performed prior to initiation of Vectibix
• Vectibix is not indicated for mCRC patients with mutant KRAS tumors or for mCRC patients with
KRAS status unknown
• Vectibix should not be administered in combination with oxaliplatin-containing chemotherapy in
mCRC patients with mutant KRAS tumors or tumors with unknown KRAS status